Abstract Background Esophageal cancer is the sixth most common cause of cancer deaths globally, and causes the deaths of over 400,000 people worldwide annually. For the patients with M1 diseases, the population has been growing over the past 20 years. Chemotherapy is the standard treatment for them, however, the survival is not satisfactory, with 5-year relative survival less than 5%. Very limited patients were able to survive more than two years. Our study aimed to evaluate the clinicopathologic characteristics of the long-time survivals and construct a clinical nomogram using the Surveilance, Epidemiology, and End Results (SEER) database. Methods Information of patients diagnosed with M1 stage esophageal cancer from 2010–2014 was retrieved from SEER database. Patients with unknown TNM stage or unknown metastatic sites were not included. Demographic and clinicopathologic characteristics were compared between LTS (long time survivals: patients who have survived for no less than 2 years) and STS (shorter time survivals: patients who have survived for less than 2 years). Cox regression analysis was performed to evaluate prognostic factors. A nomogram comprising demographic and clinicopathologic factors was established to predict 1-year survival and 2-year survival for patients with M1 diseases. Results A total of 3133 patients from the SEER database were included for analysis. The demographic and clinicopathologic variables of the LTS and the STS groups were summarized and compared. Compared with the STS, married people and patients with Grade I-II differentiated diseases were significantly more likely to be LTS. Also, LTS were associated with less bone metastasis and more surgery. Seven point three percent married patients have survived more than two years, however, only 4.5% single or divoiced or widow patients were LTS. Among the 3313 patients, 123 patients recieved surgery, and as high as 28.5% patients were LTS. The OS nomogram (Figure 1) was based on the eleven variables: gender, age, marital status, T stage, histology, grade, bone metastasis, brain metastasis, liver metastasis, lung metastasis, and surgery. Figure 1 Nomogram predicting 1-year and 2-year OS for M1 stage esophageal cancer Conclusion We developed a nomogram predicting 1- and 2-year overall survival for M1 stage esophageal cancer. The prognostic model may improve clinicians’ abilities to predict individualized survival and to make treatment recommendations Disclosure All authors have declared no conflicts of interest.